Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 130,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS members have recently turned bullish on Forest Labs
Forest Labs has already picked up a couple of FDA approvals so far this year. With partner Cypress Bioscience, it had the fibromyalgia drug Savella approved in January, to compete with Pfizer's
To see what the very best CAPS analysts are saying now about Forest Labs -- and what other winning stocks they're picking -- head on over to CAPS and have a look. Unlike analysts' opinions, which are usually reserved only for paying clients, the community research and resources in CAPS are totally free.
Motley Fool Inside Value looks for solid companies whose shares have been beaten down to dirt cheap levels. Discover the analyst team's picks for the best of Wall Street's bargain bin with a free 30-day trial.
Fool contributor Dave Mock recently upgraded his medicine cabinet with chewable vitamins and grape-flavored toothpaste. He owns shares of Pfizer, which is also an Inside Value selection. GlaxoSmithKline is an Income Investor recommendation. The Fool's disclosure policy will let you pick a toy from the prize basket if you're a good patient.